Fujifilm to develop large-scale cell culture manufacturing site in U.S.

By Nikita Chaurasia  Date: 2021-01-08

Fujifilm to develop large-scale cell culture manufacturing site in U.S.

In a bid to proliferate its biopharmaceutical contract development and manufacturing business, Fujifilm Corporation is reportedly planning to invest around USD 2 billion (200 billion yen) towards the development of a large-scale cell culture manufacturing site in the United States.

A subsidiary of this Tokyo-based multinational conglomerate, FUJIFILM Diosynth Biotechnologies, which also has production facilities in Denmark, the United Kingdom, as well as the United States will operate the new facility, cited sources with relevant information.

The new manufacturing facility will reportedly offer large-scale cell culture production capabilities of bulk drug substances with 8 x 20,000L bioreactors, with a potential to grow and add 24 x 20,000L bioreactors as per the market demand. The facility will also offer automated assembly as well as packaging and labeling services. Sources confirmed that this new site is likely to begin operations by the spring of 2025.

According to the President of Fujifilm Corp. Kenji Sukeno, the fresh investments will allow the company to develop as well as manufacture new drugs which can cater to the unmet medical demands. He added that the company intends to promote human health while supporting the growth of the healthcare sector by employing its advanced technologies and facilities to offer a continuous supply of state-of-the-art biopharmaceuticals.

Meanwhile, Martin Meeson, CEO at FUJIFILM Diosynth Biotechnologies mentioned that the Japanese conglomerate will deploy its expertise in biopharmaceutical development as well as manufacturing for producing vaccines, gene therapies, recombinant proteins, and antibodies.

Fujifilm is focusing on expanding its end-to-end service offerings throughout its biopharmaceutical CDMO businesses, sources claimed. The company reportedly invested around USD 928 million in its Denmark site FUJIFILM Diosynth Biotechnologies' Hillerød, to boost its cell culture production capacities as well as to add commercial-scale drug manufacturing capabilities.

It is worth mentioning that Fujifilm intends to achieve a yearly revenue of USD 2 billion for its biopharmaceutical CDMO (contract development and manufacturing) business by March 2025. Reportedly, the company believes that the fresh investment will boost its bio CDMO business annual growth rate to 20%, exceeding market predictions.

Source Credits –

https://www.prnewswire.com/news-releases/fujifilm-to-invest-over-200-billion-yen-2-billion-usd-to-establish-new-large-scale-cell-culture-manufacturing-site-for-biopharmaceuticals-in-the-usa-301202418.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

BMW Group to opt for green steel in vehicle production from 2025

BMW Group to opt for green steel in vehicle production from 2025

By Nikita Chaurasia

As climatic changes and other environmental issues take center stage, the BMW Group, to minimize carbon dioxide (CO2) emissions at the core of its supply chain, has reportedly agreed to use green steel from Swedish firm H2 Green Steel beginning in 20...

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

By Nikita Chaurasia

Tech giant Apple, Inc. has recently unveiled the 16-inch MacBook Pro, which promises extraordinary design and performance. The model can be customized with the all-new M1 Pro and M1 Max processors.    These new 10-core processors are ...

Kedrion Biopharma expands to North America with Prometic acquisition

Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia

Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency. This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease. Kedrion Biopharma Inc. has...

Facebook Pages to reduce focus on Likes and followers for Indian users

Facebook Pages to reduce focus on Likes and followers for Indian users

By Nikita Chaurasia

Facebook Inc. has reportedly removed Likes from Facebook Pages for its Indian users to make the platform more user-friendly and easier to understand. This redesign of Facebook Pages was launched in January 2021 and has been rolled out for Indian user...

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

By Nikita Chaurasia

India is likely to witness a record number of IPOs this year, with several companies eyeing public listing to raise funds if the market sentiment remains positive. One such company, Pine Labs is reportedly planning to list itself on Nasdaq by October...